Fairvalue-Calculator Fairvalue-Calculator
EN DE

Dna Group (DNA) Fair Value & Analysis

Consumer Cyclical · Il · Market cap 921M ILA

Price0.9710 ILA
Fair Value0.2700 ILA
Upside-72.2%
Quality92/100
Evidence: High Range 0.2400 ILA – 0.3000 ILA

Analysis

Dna Group (DNA) currently trades at 0.9710 ILA, while our model-based Fair Value estimate is 0.2700 ILA — implying the stock looks roughly 72.2% overvalued today. We read business quality at 92/100 (high quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physicians, nurses, and operators in hospitals and clinics, as well as in pharmacies and other places. In addition, it engages in the development of oral drugs. The company was formerly known as D.N.A Biomedical Solutions Ltd. and changed its name to Dna Group (T.R.) Ltd in November 2022. Dna Group (T.R.) Ltd was incorporated in 2004 and is based in Tel Aviv-Yafo, Israel.

Open the full interactive analysis →

Similar stocks

Marriott International, Inc (MAR) -76% Hilton Worldwide Holdings (HLT) -68% InterContinental Hotels Group (IHG) -55% Hyatt Hotels Corporation (H) -71% H World Group (H1TH34) -5% Accor SA (ACRFF) -22%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.